Veerhealth Care Reports Strong Q1FY27 Results, Driven by High Growth and Global Expansion

Veerhealth Care Reports Strong Q1FY27 Results, Driven by High Growth and Global Expansion​

Veerhealth Care Limited, a fast-growing company specializing in Vegan Ayurvedic and Herbal Cosmetic products through its Ayuveer brand, announced its un-audited financial highlights for the first quarter of FY27. The results reflect substantial growth across key operational metrics while highlighting significant strategic achievements, including receiving USFDA clearance for its Drug (OTC) exports.

The company focuses on crafting ayurvedic medicines and oral care products using natural ingredients, maintaining a commitment to both quality and affordability in the market.

Q1FY27 Standalone Financial Highlights​

Veerhealth Care demonstrated robust performance during Q1FY27. The highlights are as follows:


In addition to the consolidated financial figures, company leadership reported that Q1FY27 saw a Highest ever Quarterly Total Income of 725.09 crore, attributed to expanded international and domestic presence.

Key Operational Achievements and Orders​

Veerhealth Care has advanced its operational capabilities significantly through strategic milestones and secured several high-value orders during FY27.

Market and Compliance:
The company successfully received USFDA clearance for Drug (OTC) products, which enables exports to the USA and unlocks access to other international markets, underscoring its "Local to Global" vision. This qualification places Veerhealth Care in a distinctive category among small-cap companies in India within the Food & Drug (OTC) segment. Furthermore, discussions with a major Russian group for oral care exports have entered advanced stages, suggesting entry into the Russian market soon.

Domestic and International Orders:
Orders announced till date in FY27 include:

• A New York based company placed an order aggregating to 3293 Lakhs for body care products.
• India's leading large retail network of pharmacies and healthcare companies secured an order amounting to X111 Lakhs.
• One of India's Fast Moving Consumer Goods (FMCG) company provided an order for skincare products valued at 21824.40 Lakhs.
• A sample order worth 215.74 Lakhs was received from an established buyer in Sudan, marking the company’s first strategic entry into the African market.

Manufacturing and Retail Expansion:
Operationally, Veerhealth Care has commenced production at a new facility that includes in-house plastic molding for packaging and backward integration. The company has also completed the onboarding of Ayuveer products across multiple e-commerce platforms including Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.

Future Projections and Management Outlook​

Mr. Bhavin Shah, Managing Director of Veerhealth Care Limited, commented on the financial performance, noting that the Q1 progress was driven by expanding international footprint and strengthening domestic presence. He stated that securing multiple high-value export orders underscores the trust in product quality.

Looking forward, the company provided income projections for the coming fiscal years:

• In FY2026-27, Total Income is expected to be 105 crores with a Net Profit (PAT) of a minimum of ₹ 5-6 crores.
• For FY2027-28, Total Income is projected at 156 crores, targeting a minimum PAT of ₹ 9-10 crores.

The company also noted that the India-EU Trade Deal 2026 is set to transform Modern Ayurveda exports from India, creating new growth opportunities in the global wellness market.

Stock Price Movement​

Veerhealth Care Ltd shares settled at ₹46.69 on Friday, edging higher by 0.37% in post-market trading. The stock moved within an intraday range, trading between a low of ₹44.20 and a high of ₹48.80.